Get the Stockscreener App
906.70
1.18%
-10.80
After Hours:
911.47
4.77
+0.53%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $906.70, with a volume of 4.81M.
It is down -1.18% in the last 24 hours and down -10.19% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$917.50
Open:
$910.55
24h Volume:
4.81M
Relative Volume:
1.53
Market Cap:
$809.68B
Revenue:
$65.18B
Net Income/Loss:
$20.64B
P/E Ratio:
40.14
EPS:
22.5894
Net Cash Flow:
$5.96B
1W Performance:
-7.96%
1M Performance:
-10.19%
6M Performance:
+20.57%
1Y Performance:
+7.61%
1-Day Range:
$899.29
$925.38
1-Week Range:
$899.29
$998.17
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
906.70 | 809.68B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
235.37 | 566.92B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
205.07 | 362.60B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
183.60 | 284.73B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
114.18 | 282.30B | 64.93B | 18.26B | 12.36B | 7.2751 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly's diabetes drug cuts weight by 17% in trial - qz.com
Eli Lilly and Company (LLY) Expands Zepbound Access as Pricing Reforms Boost Long-Term Growth Outlook - Insider Monkey
Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics - AOL.com
Eli Lilly (LLY) Downgraded by HSBC Amid Valuation Concerns - GuruFocus
Eli Lilly and Co. shares update on LEAP construction, workforce development - Inside INdiana Business
Best Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals - AOL.com
Should You Buy Eli Lilly Stock Before April 10? - The Motley Fool
Media Statement: Zepbound (tirzepatide) KwikPen now available at self-pay pricing at major pharmacies nationwide in addition to LillyDirect - Eli Lilly
Sagespring Wealth Partners LLC Has $10.59 Million Stake in Eli Lilly and Company $LLY - MarketBeat
Should You Buy Eli Lilly Stock Before April 10? - The Motley Fool
The stock prices of Eli Lilly and Novo Nordisk, which have divided the global obesity treatment mark.. - 매일경제
Eli Lilly's Market Outlook: Weight Loss Drugs, Competition, and Portfolio DiversificationNews and Statistics - IndexBox
India is well positioned to attract future investments: Patrick Johnson, President, Lilly International - The Economic Times
Eli Lilly & Co Slides as Bold Pipeline Tested - TipRanks
Is Eli Lilly (LLY) Still Attractive After Its Multi Year Share Price Surge - simplywall.st
AI Models Split on Eli Lilly (LLY) as Growth Story Meets Rich Valuation - TipRanks
Union Bancaire Privee UBP SA Sells 3,199 Shares of Eli Lilly and Company $LLY - MarketBeat
BMO Capital Remains a Buy on Eli Lilly & Co (LLY) - The Globe and Mail
Eli Lilly and Company $LLY Shares Purchased by Neville Rodie & Shaw Inc. - MarketBeat
Park Avenue Securities LLC Acquires 2,711 Shares of Eli Lilly and Company $LLY - MarketBeat
GAMMA Investing LLC Raises Holdings in Eli Lilly and Company - National Today
Coastline Trust Co Has $21.74 Million Position in Eli Lilly and Company $LLY - MarketBeat
GAMMA Investing LLC Raises Holdings in Eli Lilly and Company $LLY - MarketBeat
Anderson Hoagland & Co. Has $22.12 Million Position in Eli Lilly and Company $LLY - MarketBeat
Beijing courts Eli Lilly as weight-loss drug race drives $3bn China commitment - Investing.com
Eli Lilly and Company $LLY Shares Bought by AIA Group Ltd - MarketBeat
China Commerce Minister Hopes Lilly Will Deepen China Commitment - Bloomberg.com
Eli Lilly Beats 9th Circ. Appeal Over Brain Bleed After Cialis - Law360
ELI LILLY & Co ($LLY) CEO 2025 Pay Revealed - Quiver Quantitative
Eli Lilly and Company (NYSE:LLY) Shares Down 1.3%What's Next? - MarketBeat
Eli Lilly and Company (LLY) Announces Positive Topline Results From the Phase 3 ADorable-1 Trial - Insider Monkey
Eli Lilly (NYSE: LLY) 2026 proxy outlines pay, performance and governance votes - Stock Titan
Stock Quote & Chart | Eli Lilly and Company - Eli Lilly
Eli Lilly & Co. stock faces pressure amid pipeline setbacks and GLP-1 competition - AD HOC NEWS
Scotiabank Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,300 - 富途牛牛
Why Eli Lilly Remains My Top Obesity Bet (NYSE:LLY) - Seeking Alpha
Jim Cramer says "Buy Eli Lilly" - MSN
Jim Cramer Says “Buy Eli Lilly” - Insider Monkey
Lilly-partnered Fauna announces designation of novel obesity target - The Pharma Letter
Eli Lilly stock price forecast for 2040: Drug innovation pipeline supports long-term outlook towards $2,500 - Traders Union
Eli Lilly (LLY) Faces Reevaluation of Alzheimer's Drug Decision - GuruFocus
Lilly’s manufacturing bet; hints of a biotech revival - Pharma Voice
Long Acting Injectables Market Is Going to Boom |Eli Lilly - openPR.com
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $1,250 to $1,500 - 富途牛牛
Eli Lilly (LLY) and Biogen (BIIB) Alzheimer's Drug Review by UK Watchdog - GuruFocus
Swiss Life Asset Management Ltd Raises Stock Position in Eli Lilly and Company $LLY - MarketBeat
Lilly GLP-1 drug rivals Novo's pipeline treatment on gut side effects but throws up skin concern - Proactive financial news
Mirova Decreases Stake in Eli Lilly and Company $LLY - MarketBeat
Mainstay Capital Management LLC ADV Has $1.17 Million Holdings in Eli Lilly and Company $LLY - MarketBeat
England to Review Rejection of Alzheimer’s Drugs for NHS - Bloomberg.com
Allworth Financial LP Acquires 5,249 Shares of Eli Lilly and Company $LLY - MarketBeat
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):